Anti-Mouse B220 Antibody (RA3.3A1/6.1) 

Anti-Mouse B220 Antibody (RA3.3A1/6.1) is a rat-derived IgM type antibody inhibitor, targeting to mouse B220. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can deplete B cells. Anti-Mouse B220 Antibody (RA3.3A1/6.1) can be used for the researches of cancer and immunology, such as 4T1 and B16 tumor^[1][2].

Rat IgM

Mouse

B220

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse B220 Antibody (RA3.3A1/6.1) (400 μg, i.p., at days 3, 10 and 18) depletes B220⁺ cells and almost completely abrogates lung metastases in 4T1 tumor mice^[1].
Anti-Mouse B220 Antibody (RA3.3A1/6.1) (300 μg, i.p., three weeks before tumor inoculation and every 5 days thereafter) depletes B cells and accelerates tumor development and delays or prevents tumor rejection in B16 tumor mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

19264  [NCBI]

P06800

in vivo B cell depletion; in vitro B cell negative selection

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Mouse B220 Antibody (RA3.3A1/6.1)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Olkhanud PB, et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res. 2011 May 15;71(10):3505-15.  [Content Brief]

  [2]. Carmi Y, et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature. 2015 May 7;521(7550):99-104.  [Content Brief]